INmune Bio
INMB
5 hedge funds and large institutions have $352K invested in INmune Bio in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.52% more ownership
Funds ownership: 0% → 0.52% (+0.52%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$258K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$78.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.36K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$1.55K |
| 5 |
BlackRock
New York
|
+$1.42K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $261K | +$258K | +33,333 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $80K | +$78.9K | +10,191 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $9K | +$9.36K | +1,209 | New |
|
|
4
BlackRock
New York
| $1K | +$1.42K | +184 | New |
|
|
FIA
5
FNY Investment Advisers
New York
| $1K | +$1.55K | +200 | New |
|
INMB Hedge Fund Activity: Q1 2019 in Review
5 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q1 2019, worth a combined $352K.
Buyers outnumbered sellers: 5 funds opened new INMB positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $258K.
- 5 institutional investors held INmune Bio (INMB) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $352K of INmune Bio stock for Q1 2019.
- 5 funds opened new INmune Bio positions in Q1 2019 and 0 closed out, a net change of +5 holders.
- The largest INmune Bio buyer in Q1 2019 was Deutsche Bank, an estimated $258K added.
Based on aggregated 13F filings for Q1 2019.